GC
APGE

Guggenheim Capital’s Apogee Therapeutics APGE Stock Holding History

Guggenheim Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Buy
14,783
+1,365
+10% +$123K 0.01% 743
2026
Q1 		$1.13M Buy
+13,418
New +$974K 0.01% 948

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Guggenheim Capital's APGE Position: Q2 2026 in Review

Guggenheim Capital increased its Apogee Therapeutics (APGE) stake by 10% in Q2 2026, buying an estimated $123K and bringing the position to 14,783 shares worth $1.96M. The position accounts for 0.01% of the portfolio, ranked #743.

Guggenheim Capital first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Guggenheim Capital held 14,783 shares of Apogee Therapeutics worth $1.96M as of Q2 2026.
  • Guggenheim Capital bought 1,365 Apogee Therapeutics shares in Q2 2026, an estimated $123K.
  • Apogee Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #743 holding.
  • Guggenheim Capital first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.